Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Ajanta Pharma (Initiating Coverage) - Gearing for the next leap - HDFC Securities

Posted On: 2021-01-25 09:33:54 (Time Zone: Arizona, USA)

Ms. Bansi Desai, Institutional Research Analyst, HDFC Securities

Ajanta Pharma is a diversified branded play with best-in-class return metrics. Its high exposure to branded generics markets (70%+ revenue from India, Asia and Africa) offers sustainable growth visibility with superior profitability. Rising scale in the US business is expected to drive margin expansion and increased contribution to the overall profits. With the conclusion of major capex cycle (Rs16bn+ in the past 6 years, internally funded) and plant opex reflecting in P&L, operating leverage benefits are expected to drive strong earnings growth of 18% CAGR, core-ROCE expansion of ~550bps to 28% and FCF generation of ~Rs13bn over FY21e-FY23e. Initiate with a BUY and target price of Rs2,150/sh.

Niche franchise in India; cardiac, ophthal and derma form ~80% of revenue: Ajanta's distinctive strategy of launching novel first-to-market products (~50%+ of portfolio) has driven its outperformance of ~200bps vs. the IPM in the ast five years. With a recovery in domestic market, we expect India business to grow at ~14% CAGR over FY21e-23e driven by volume growth and new launches. It has managed to held its market share in the lockdown period, which is noteworthy.

Strong traction in the US to continue, margin trajectory to improve: Despite Ranitidine recall (~10% of FY20 sales), US revenue maintained strong growth momentum driven by market share gains in older products. US business (~USD80mn, doubled in 2 years) is expected to grow at ~18% CAGR over FY20- 23e on the back of 8-10 launches per year. Recent approvals - gTamiflu suspension, gDepakote ER, Dapagliflozin (tentative) - provide growth visibility in the near to medium term. With rising scale, EBITDA margins are set to improve over the next two years.

Asia business has reasonably good outlook; Africa stabilises: Asia business is expected to grow at ~13% CAGR driven by steady performance in Phillipines (40% of Asia revenues), new launches and volume growth. Africa business has a stable outlook (branded biz to grow in high single digit, institutional biz to remain flat).

Unleveraged balance sheet; strong FCF generation and RoCE improvement: Ajanta's aggressive capex coincided with several business headwinds (decline in institutional business, currency volatility in EMs, slowdown in IPM), depressing its core-RoCE from 40%+ five years back to ~18% in FY20. Despite the capex, the company remained net debt free and FCF positive. With improving utilisations and asset turns, we expect strong FCF generation of ~Rs13bn and core-ROCE expansion of ~550bps to 28% over FY21e-23e.

Our target price of Rs 2,150/sh provides ~25% upside potential; risks: We value Ajanta at Rs 2,150/sh, based on 23x Mar'23e EPS, largely in line with its 5-year historical average PER. Risks: expansion of NLEM list, lower growth in EMs including India, delay in US approvals, and currency volatility in EMs.

Shares of AJANTA PHARMA LTD. was last trading in BSE at Rs.1748.05 as compared to the previous close of Rs. 1721.35. The total number of shares traded during the day was 11241 in over 1547 trades.

The stock hit an intraday high of Rs. 1792.45 and intraday low of 1698.75. The net turnover during the day was Rs. 19807520.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Nestle India 1QCY21 results - Views by Himanshu Nayyar, Lead Analyst - Institutional Equities, YES SECURITIES

ICICI Prudential Life Insurance - Q4FY21 Result Update - YES Securities

Power: Sector Thematic - Reforms essential for renaissance - HDFC Securities

ACC 1QCY21 Results Review Report - Strong margins! - HDFC Securities

ICICI Prudential Life 4QFY21 Results Review Report - Strong micro; challenging macro - HDFC Securities

ACC Ltd - Q1CY21 Result Update - YES Securities

ICICI Prudential Life Insurance - Business momentum upwards; valuations remain attractive - ICICI Securities

Multiplex - Business disruption again - learnings and better cash position to help - ICICI Securities

ACC - Strong show led by lower costs - ICICI Securities

Brookfield India REIT - Building a strong edifice - ICICI Securities

Q4FY21 Result Preview - Oil & Gas - ICICI Direct

Q1CY21 Result Update - ACC Ltd - ICICI Direct

ACC Q1CY21 Results - Views by YES SECURITIES

Comments on Rupee from industry experts - April 19, 2021

Autos & Logistics 4QFY21 Results Preview - HDFC Securities

ADD on Mindtree - Gaining momentum - HDFC Securities

ICICI Lombard 4QFY21 Result Review - HDFC Securities

Mindtree - Q4FY21 Result Update - YES Securities

ICICI Lombard - Q4FY21 Result Update - YES Securities

HDFC Bank - Q4FY21 Result Update - YES Securities

Mindtree - Subtle downgrade in outlook! - ICICI Securities

SBI Cards and Payment Services - Play on monetisable payments growth - ICICI Securities

ICICI Lombard General Insurance Company - Cyclical recovery can protract; fundamentals remain intact - ICICI Securities

HDFC Bank - Resilience and consistency displayed to its core - ICICI Securities

Home First Finance Company - Tech-led affordable housing play at affordable valuations - ICICI Securities

Q4FY21 Result Update - Wipro Ltd - ICICI Direct

ICICI Direct - Covid Recovery Pulse - E-Way bill generation ends March 2021 on strong note...

Derivatives Strategy - Positional Future - ICICI Direct

Gladiator Stocks - Escorts - ICICI Direct

Q4FY21 Company Update - Tata Metaliks - ICICI Direct

Q4FY21 Result Update - MindTree Ltd - ICICI Direct

Q4FY21 Result Update - HDFC Bank - ICICI Direct

ICICI Direct Derivatives Weekly View (April 16): Sustainability above 14700 may trigger fresh uptrend...

Market Outlook - Technical - By Dharmesh Shah, Head - Technical, ICICIdirect

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on Monsoon outlook

ADD on Wipro - Improving growth visibility - HDFC Securities

Building Materials 4QFY21 Results Preview - Strong demand to support robust margin - HDFC Securities

Consumer Discretionary 4QFY21 Results Preview - Bargains few and far between - HDFC Securities

Consumer Durables 4QFY21 Results Preview - HDFC Securities

Wipro - Q4FY21 Result Update - YES Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on March 2021 Monthly Trade Balance

Wipro - Q4FY21 Result Update - Lofty multiples leave limited margin of safety - ICICI Securities

FMCG & Alco Bev 4QFY21 Results Preview - HDFC Securities

Maintain BUY on Infosys - Q4FY21 Results Review - Buy the dip - HDFC Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on March 2021 WPI Data released today

Non-leveraged financials 4QFY21 Results Preview - HDFC Securities

Infosys - A reality check! - ICICI Securities

Infosys - Q4FY21 Result Update - YES Securities

Polymer price tracker - PVC prices continue to rise - April 15, 2021 - ICICI Securities

Bharti Airtel - Restructuring aimed at digital biz, AGR-tax efficiency - ICICI Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020